Member Info for allah4uk

Also notice how Graham said "Novacyt's strengthened financial position also means we are able to redefine our R&D pipeline for the next three years".

A 3 year visibility, at least on the research side, should please the investors.

Sheeeeeeeetttt so they were indeed working on an antibody test !

I feel it's the news that'll really proper the SP.

We're on a 1h schedule with the Q16 + Exsig Direct. That's already pretty competitive.

If and once the One Step vials are released, we'll be closer to that 45 mins performance.

What happened is that you were perfectly happy with an infamous liar diffusing his false information in a supposedly informative thread, at which point we had to step in to give the rest of AVCT holders a reality check.

In fact, the core issue here is less what you write about other companies, and more the fact that you're happy to support shameless dishonesty. This tells a lot about you as a person, and not in a good way.

Who wouldn't want to post in a board where properly researched information is shared with other investors, as opposed to "discussing" random ****** ?

What's the point of posting here if every other person is writing useless lies ? What benefit can it possibly bring ?

Who in his right mind wouldn't be worried about dishonesty ?

Compare all you want, be our guest. But at least have the decency to make a honest comparison.

I'll let AVCT shareholders will make their own mind as to whether NCYT's instrument is the size of "a transit van" - or whether CaptainStanley is spewing utter drivel as usual : https://blog.primerdesign.co.uk/international-animal-rescue-to-use-primerdesign-genesig-q16-and-selected-assays/

I think at the end of the month they'll release Phase 1 of their portable system at the end of the month, that is the Q16/32 + Exsig Direct ; which is a simplified version of the original test kit.

Then once they're done developing the pre-mixed coating, they'll advance into Phase 2, upgrading that portable system in the form of the Q16/32 + One Step test.
Hopefully they're only one or two months away from that.

Once this happens, NCYT will have nullified GDR's unique selling point.

And the good thing is, current prospective customers won't be deterred by this evolution path, since they'll be able to re-use the Q16/32 they bought and simply drop-in the One Step vials once they're commercialised.

Balanced, NCYT might be using their "Covid-HT" test, originally intended for intensive lab testing : http://novacyt.com/wp-content/uploads/2020/06/Novacyt-Launch-Exsig-and-HT-ENGLISH-18.06.2020.pdf

It'd make a lot of sense to bring it on the field too : quicker and less error prone.

There is a lot of commercial potential with the products involved. However it's not me who has to be convinced that NCYT's products are good. It's the markets. And what makes the markets happy is not just the release of new products, but their validation by relevant actors on top of that. If they're not given this, the SP won't budge much, if at all.

This is why I believe it's important to recognise the current state of affairs, which is that NCYT's products are being trialed by an institution, which could help us boost our profile. That's actually a positive thing. And yes I'm pretty sure that we'll pass this with flying colours, but that's not the point, since I never alleged that we'd fail in the first place.

The problem lies with the rose-tinted rampers who keep denying that a trial is actually taking place, even though this is the objective reality. And by being unable to spell this very reality, they skew the collective vision of private investors regarding the necessary steps that NCYT must pass in order to improve its already high profile as well as its order book.

This is exactly what is at stake for NCYT. It isn't enough to say that their products are already individually certified and that on paper they'll do the job. That's not how companies operate in the real world.

In reality you need your product to be endorsed by relevant entities that will send a signal to the market. Hence the importance of having a scientific institution properly trial your products, and hopefully validate their usefulness with hard numbers. This will serve to unlock further contracts.

Indeed Simple00, it's probably time to end the conversation here since your unwarranted positivity is starting to irk me. Have a good week-end and may Allah bless your soul nonetheless.

Simple00 : so why is QMUL saying they're doing an experiment ?

Simple00 : you are nitpicking. Whether they evaluate the test itself, or its deployment in a given setting, either way it's a trial.

It didn't make too much sense that it'd be us given that QMUL hasn't even finished its trials of the Q16.

Then again, the Tories have a good track record of buying untested equipment through half-baked schemes.

Interesting lead. Anyone knows if the contract with GenePOC came to materialise, or if it's been shelved following the acquisition by Meridian ?

Cuz a looking at the website, what NCYT was to develop isn't advertised : https://www.meridianbioscience.com/platform/molecular/revogene/

Meh. That guy has a history of talking out of his arsch.

"Someone posted a document 10 minutes ago but she’s deleted it now!!!"
Yeah and who is that bright female person ? He's unable to give any clue as to who that person is nor what kind of document was posted.

Moral of the story : stop wasting your and my time with morons.

Great initiative Coke, I was wondering about that as well.

I hope they'll find enough volunteer care homes ASAP, so that we can get a good news quickly.
This could be big, as a positive experiment would validate the calls for systematic testing.

As for posting email contents on a forum : it's good etiquette to ask the other party beforehand, and thereafter to specify that such agreement has been given.

It's just the saliva qualification of the standard PCR test.

Thanks CocaColaKid for this write up, much appreciated.